Corpus Intelligence IC Memo — KULA HOSPITAL 2026-04-26 15:42 UTC
IC Memo — KULA HOSPITAL
Investment Committee Memorandum | HI | 9 beds | Grade D | EBITDA uplift $1.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

KULA HOSPITAL

CCN 121308 | MAUI, HI | 9 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

KULA HOSPITAL is a 9-bed community hospital in MAUI, HI with $23.3M in net patient revenue and a -71.2% operating margin. The hospital serves a payer mix of 26.0% Medicare, 0.0% Medicaid, and 74.0% commercial.

Thesis: Turnaround. Our ML models identify $1.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -71.2% to -63.8% (+736bps).

Net Revenue HCRIS$23.3M
Current EBITDA COMPUTED$-16.6M
Operating Margin COMPUTED-71.2%
Occupancy HCRIS27.6%
Revenue / Bed COMPUTED$2.6M
Net-to-Gross HCRIS60.6%
Distress Probability MLnan%

2. Market Context & Competitive Position

26
HI Hospitals
-14.7%
State Median Margin
483
Comparable Hospitals

HI has 26 Medicare-certified hospitals with a median operating margin of -14.7%. The target's margin of -71.2% places it below the state median. Among 483 size-comparable peers (4-18 beds), the median margin is -8.4%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (4-18), prioritizing same-state peers. 483 hospitals in the comp set.

HospitalStateBedsRevenueMargin
KULA HOSPITAL (Target)HI9$23.3M-71.2%
WENATCHEE VALLEY HOSPITALWA11$277.5M-4.9%
PORTERVILLE DEVELOPMENTAL CENTCA17$193.6M-6.0%
NATIONAL JEWISH HEALTHCO13$150.4M-50.0%
NORTON SOUND REGIONAL HOSPITALAK18$148.7M-28.6%
FRANCISCAN HEALTH HAMMONDIN10$117.7M-4.3%
NEW YORK EYE AND EAR INFIRMARYNY15$112.8M-28.0%
OAK LEAF SURGICAL HOSPITAL LLCWI13$109.8M34.1%
SOUTHERN MONO HEALTH CARE DISTCA17$99.1M4.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$490K+210bp18mo
Cost to Collect4.5%2.5%$466K+200bp12mo
Denial Rate Reduction12.0%6.5%$462K+198bp12mo
A/R Days Reduction5200.0%3800.0%$284K+122bp9mo
Clean Claim Rate88.0%96.0%$15K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$490K
Cost to Collect
$466K
Denial Rate Reduction
$462K
A/R Days Reduction
$284K
Clean Claim Rate
$15K
Total EBITDA Uplift$1.7M
Current EBITDA$-16.6M
+ RCM Uplift+$1.7M
Pro Forma EBITDA$-14.9M
Current Margin-71.2%
Pro Forma Margin-63.8%
WC Released (1x)$894K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-25.5M$-92.3M0.00x-100.0%
Base (11x exit)10.0x11.0x$-25.5M$-109.9M0.00x-100.0%
Bull Case9.0x11.0x$-23.0M$-112.5M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-23.0M$-129.5M0.00x-100.0%
Bear Case11.0x10.0x$-28.1M$-92.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-28.1M$-111.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 27.6%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 483 hospitals with 4-18 beds
  • Same-state prioritization (n=5)
  • Comp margins: P25=-25.1% / P50=-8.4% / P75=2.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.